Best HSCT Hospitals and Medical Centers in the World for MS & Autoimmune Diseases

How HSCT Stops Multiple Sclerosis and Other Autoimmune Diseases.

Hematopoietic Stem Cell Transplantation (HSCT) is the only treatment proven to halt — and in many patients, reverse — the progression of Multiple Sclerosis and a range of other autoimmune conditions. Rather than managing symptoms, HSCT targets the underlying cause: a misdirected immune system that attacks the body’s own nervous tissue.

The procedure works by ablating the faulty immune system using a short, targeted course of chemotherapy, harvesting the patient’s own haematopoietic (blood-forming) stem cells beforehand, and then reintroducing them to rebuild a healthy immune system — one without the cellular “memory” that drives autoimmune attack. This immune reset is clinically described as a “reboot.”

The landmark MIST Trial (Burt et al., JAMA 2019) demonstrated that autologous HSCT was significantly more effective than the best available disease-modifying therapies for relapsing MS, with 60% of HSCT patients achieving NEDA-3 (No Evidence of Disease Activity) at five years, compared to 23% in the DMT group.

The modern HSCT programme for autoimmune diseases was pioneered by Dr Richard Burt at Northwestern University, Chicago, who began his work in 1996. Building on research conducted as a Fellow at Johns Hopkins Hospital, Dr Burt theorised that if diseased immune cells could be eliminated, a newly reconstituted immune system would lose its autoimmune “memory.” He validated this in animal models before translating it to human clinical trials — work that now spans nearly 30 years and includes conditions beyond MS, including CIDP, Myasthenia Gravis, Crohn’s disease, and autoimmune Small Fiber Neuropathy.
More than 5,000 patients have been treated for MS with HSCT worldwide. The procedure has been performed for nearly three decades, with on going refinements improving both safety and efficacy substantially since the early 1990s.

Side-by-Side Comparison of Major HSCT Centres across the world.

Top  HSCT Centres Worldwide

Each of the following centres has a recognised track record in HSCT for MS or other autoimmune diseases. They vary significantly in cost, eligibility criteria, and what is included in the treatment.

1. HSCT Hospital India — New Delhi NCR, India

HSCT Hospital India is a JCI-USA accredited medical centre running one of the world’s most accessible and well-regarded HSCT programmes for Multiple Sclerosis and other autoimmune diseases. The unit is supported by an in-house world-class blood bank, haematopathology, microbiology, histopathology, radiology, and a sophisticated ICU — plus allied specialties including neurology, cardiology, gastroenterology, and nephrology. The $30,000 all-inclusive package covers all tests, consultations, chemotherapy, stem cell procedures, HEPA-filtered room accommodation for patient and attendant, medications, and meals for 30 days.

Eligibility: All MS subtypes (RRMS, SPMS, PPMS). CIDP, NMO, SFN, MG, Stiff Person Syndrome. No mandatory prior DMD failure. International patients welcomed. Remote evaluation available.

2. Northwestern Memorial Hospital — Chicago, USA

Home to Dr Richard Burt — widely regarded as the father of HSCT for autoimmune disease — Northwestern is the programme against which others are benchmarked. It carries the highest volume of MS transplants in North America and has published the most clinical trial data. Access for international patients is possible but at significant cost.

Eligibility: Predominantly RRMS; active disease preferred. Assessed case-by-case. Requires neurologist referral.

3. HSCT Mexico — Clínica Ruiz — Puebla, Mexico

HSCT Mexico, operated by Clínica Ruiz under Dr Ruiz Argüelles and Dr Gómez-Almaguer, is one of the world’s highest-volume private HSCT centres for autoimmune disease, with over 1,900 HSCT procedures for MS and 3,500+ total across 20+ years. Transplant-related mortality is under 0.26% — among the lowest published globally — and positive results have been achieved in over 80% of patients, including progressive cases. Treats a wide range of conditions: MS (all subtypes), CIDP, NMO, MG, Ankylosing Spondylitis, Sjögren’s Syndrome, Scleroderma, SLE, and Type I Diabetes.  Key practical consideration: Unlike hospital-based programmes, patients stay in serviced apartments in Puebla (not hospital rooms), visiting the clinic for treatment sessions. There are no HEPA-filtered inpatient rooms. A mandatory caregiver is required throughout the 28-day stay; Clínica Ruiz offers a caregiver service at an additional $3,000 USD. Full payment is required two months in advance. The programme is not JCI accredited.

Eligibility: All MS subtypes (RRMS, SPMS, PPMS). EDSS up to 7. 0 accepted; 7.0–8.0 case-by-case; above 8.0 not accepted. No general age restriction. All DMDs must be stopped 3 months prior. International patients accepted.

4.AHSCT Russia — National Medical & Surgical Centre  —  Moscow, Russia

AHSCT Russia operates from the Hematology and Cell Therapy Department of the National Medical and Surgical Centre in Moscow — an 18-department federal hospital complex. The programme is led by Dr Denis Fedorenko, one of the world’s most published HSCT physicians, with over 3,000 patients treated across 20 years and a reported 75–95% MS stabilisation rate. The facility uses dedicated isolation rooms with integrated air/water purification and strict aseptic protocols — a full hospital-grade inpatient environment. The all-inclusive contract covers pre-transplant examinations, full inpatient accommodation, 24/7 specialist observation, nutrition, visa assistance, and airport transfers. Conditions treated include MS (RRMS, SPMS), CIDP, SLE, Systemic Sclerosis, Crohn’s Disease, ME/CFS, Stiff Person Syndrome, MG, RA, Sjögren’s Syndrome, NMOSD, and Vasculitis. Note: Access to Russia has become significantly more complex for nationals of many Western countries since 2022. Verify current visa accessibility for your nationality before applying.

Eligibility: Age 16–70. EDSS 1.5–6.5 for MS (higher EDSS considered case-by-case after protocol upgrade). Negative HIV/HBV/HCV required. No severe organ dysfunction. All immunomodulating drugs stopped 3–6 months prior. International patients accepted subject to current visa and travel access.

5. Sheffield Teaching Hospitals NHS Foundation Trust—Sheffield, UK

A centre of excellence for HSCT research in the UK with dedicated clinical research infrastructure. NHS-funded treatment is available for qualifying UK residents; international patients cannot access the programme on NHS terms. Private access is available at substantially higher cost.

Eligibility: RRMS with ≥2 failed DMDs and active MRI lesions. Progressive MS not routinely accepted. UK residents primarily.

6.Heidelberg University Hospital  —  Heidelberg, Germany

One of Europe’s largest haematology and oncology centres. The transplant programme under Professor Carsten Müller-Tidow has extensive experience in both haematological malignancies and autoimmune HSCT.

Eligibility: Generally RRMS; ≥2 failed DMDs and active lesions typically required.

7.The Ottawa Hospital MS Clinic  —  Ottawa, Canada

Canada’s leading publicly funded HSCT programme for MS. One of the country’s largest learning and research hospitals. Access requires neurologist referral. Not available to international patients seeking private care.

Eligibility: RRMS with failed DMDs; neurologist referral required. Canadian residents only.

Seven Reasons HSCT Hospital India Is the World’s Best HSCT Destination

1. JCI-USA Accreditation:Joint Commission International (JCI-USA) accreditation is the global gold standard for hospital quality and patient safety. HSCT Hospital India holds this certification, placing it alongside the world’s leading hospitals in the US, Europe, and Asia.
2. Fraction of Western Costs: At 30,000 US Dollars all-inclusive, HSCT in India costs 75–85% less than the same procedure in the US ($125,000–$200,000). The cost advantage is structural — driven by lower operating costs — not a reflection of any compromise in clinical quality or infrastructure.
3. Broader Eligibility Criteria: HSCT Hospital India accepts all MS subtypes including PPMS and SPMS, and does not require prior failure of two disease-modifying therapies. This opens the door for patients who have been turned away by Western centres.
4. Wide Autoimmune Condition Scope: Beyond MS, HSCT Hospital India treats CIDP, Neuromyelitis Optica (NMO), autoimmune Small Fiber Neuropathy (SFN), Myasthenia Gravis, Stiff Person Syndrome, and other autoimmune neurological conditions.
5. Complete Infrastructure On-Site: World-class blood bank, haematopathology, microbiology, histopathology, ICU, neurology, cardiology, gastroenterology, nephrology and radiology — all under one roof, meaning no transfers to other facilities during critical stages of treatment.
   
6. Double-Level HEPA Air Filtration: Every transplant room features double-level HEPA air filtration — one of the most rigorous infection-control environments available globally. This is critical during the immunosuppressed recovery period post-transplant.
7. Patient & Attendant Accommodation Included: The all-inclusive package covers hospital accommodation for both the patient and one accompanying person for the full 30-day stay in a deluxe private room with medical costs and food for the patient and one attendant also included in the package— a meaningful practical and financial advantage that US and European centres do not offer.

How to Find out Your Eligibility for Treatment at HSCT Hospital India

The evaluation process is straightforward and can begin remotely from anywhere in the world.

1. Submit Your Medical Records – Email recent MRI reports, neurologist letters, EDSS score, and current medications to info(at)hsctindia.com or Whatsapp at +91 9818098628. The HSCT Clinical team reviews all cases without charge.
2. Remote Consultation with the HSCT Team – A specialist haematologist and neurologist will review your records and conduct a video or telephone consultation to assess suitability and answer your questions.
3. Pre-HSCT Medical Evaluation (On Arrival) – A comprehensive inpatient evaluation is conducted over several days, covering all required tests and specialist assessments, included within the package cost.
4. HSCT Treatment (30 Days) – Stem cell mobilisation, harvest, conditioning chemotherapy, and reinfusion are conducted across a 30-day inpatient stay in a HEPA-filtered room with daily specialist reviews.
5. Post-Transplant Follow-Up – Preventative antibiotic and antiviral therapy for up to 12 months post-transplant. Ongoing haematology follow-up can be coordinated with a local specialist in the patient’s home country.

Real Patient– Real Stories